ROCHESTER, NY – Vaccinex Inc., a clinical stage biotechnology company focused on the development of novel immune-based therapeutics has presented information regarding VX15/2503, the company’s leading therapeutic antibody program. A poster was available for viewing at the 50th annual American Society of Clinical Oncology (ASCO) entitled “Phase 1 Study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts)” on June 1, 2014 in Chicago, IL. VX15/2503 antibody targets semaphorin 4D (SEMA4D).

SEMA4D regulates cellular adhesion, motility and activation of cells of the nervous, vascular and immune systems; it also promotes tumor progression and metastasis. SEMA4D and its receptor plexin B1 are widely expressed in human tumors; the interaction of plexin B1 with MET & ERBB2 leads to SEMA4D-mediated transactivation of these membrane receptor kinases promoting tumor cell migration and invasive growth. The murine progenitor of VX15/2503 suppressed tumor growth in syngeneic and transgenic tumors.

Enrollment for the study is concluded and VX15/2503 was well tolerated. Thirteen of 42 patients at all dose levels exhibited stable disease for at least 8 weeks with 5 of those patients exhibiting relatively elevated T or B cell levels at enrollment and one patient achieving a partial response. Future trials will focus on combination studies in selected tumor types.

A link to the pertinent presentation is provided below.
(ASCO) - Phase 1 Study of VX15/2503 in advanced cancer patients (pts)

About Vaccinex, Inc. Vaccinex, Inc. based in Rochester, New York, is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including multiple sclerosis and Huntington’s disease. www.vaccinex.com.